DuoBiopharma Initiates Phase I Clinical Trial of PSMA-Targeted ADC DEC003M for Advanced Prostate Cancer

▎Armstrong

On June 15, 2026, DAC Biotech registered a Phase I clinical trial of DEC003M for the treatment of advanced prostate cancer on the Drug Clinical Trial Registration and Information Publicity Platform website.

Based on clinical registration information, DEC003M can be identified as a novel PSMA-targeting antibody-drug conjugate (ADC).

DEC003M is administered once every three weeks via intravenous injection.

This Phase I clinical trial plans to enroll 110 patients with advanced prostate cancer, under the leadership of Director Wei Qiang and Director Feng Ping from West China Hospital, Sichuan University.

Summary

Novartis’s PSMA-targeted radiopharmaceutical Pluvicto recorded sales of $1.994 billion in 2025 and is projected to reach $3 billion in 2026. The competitive landscape for novel drugs targeting PSMA has attracted investments in various modalities, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). In the ADC space, Hengrui Pharma, Minghui Pharmaceutical, and DAC Biotech have developed PSMA-targeting ADCs and advanced them into clinical stages. Additionally, DAC Biotech has developed PSMA/STEAP1 and PSMA/B7H3 dual-targeting ADCs, RemeGen has developed a PSMA/B7H3 ADC, and Qilu Pharmaceutical has developedPSMA/STEAP1/CD3 trispecific antibodies, etc. As can be seen, DAC Biotech has extensively laid out its ADC pipeline around prostate cancer, with PSMA as the core focus.